[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:t-cell-and-nk-cell-neoplasm":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":27,"states":28},"T-Cell and NK-Cell Neoplasm",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05436418","The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation",[11],"2026-08-26T02:17:18.747857Z","2026-05-05T02:35:31.635324Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06067347","A Global Study of the PETAL Consortium",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.405928Z",[],[]]